Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNT-517 for the Treatment of Phenylketonuria
NCT06971731Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of repinatrabit in phenylketonuria (PKU), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2025; status: recruiting.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT06971731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06971731.